Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchial Asthma
Conditions
Bronchial Asthma
Trial Timeline
Oct 17, 2018 → Mar 31, 2020
NCT ID
NCT03394989About Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT is a phase 3 stage product being developed by Cipla for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT03394989. Target conditions include Bronchial Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03394989 | Phase 3 | Completed |
Competing Products
20 competing products in Bronchial Asthma
Other Products from Cipla
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVApproved
85
Insulin Lispro-aabc + Insulin GlargineApproved
85
CBT124 + EU-sourced Avastin® + Carboplatin + PaclitaxelPhase 3
77
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboPhase 3
77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboPhase 3
77